ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Adaptive Biotechnologies (NASDAQ: ADPT)
›
Adaptive Biotechnologies (NASDAQ: ADPT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 624 employees.
The shares were at 27.93 USD on 20 November 2026, up 60.9% over 52 weeks. Its 52-week range is 12.00 USD to 32.13 USD: the price is 13.1% below the high and 132.8% above the low.
Its market capitalisation is 4.52B USD.
Adaptive Biotechnologies reports return on equity of -27.2%, an operating margin of -16.2% and revenue down 10.7% year over year.
Its debt exceeds its cash by 110.02M USD, a debt-to-equity ratio of 0.36. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 33.86 USD is 21.2% above the current price. The next earnings report is expected on 4 February 2027.